Apatinib Plus Gefitinib as First-Line Treatment in Advanced EGFR-Mutant NSCLC: The Phase III ACTIVE Study (CTONG1706)
Hongyun Zhao, Wenxiu Yao, Xuhong Min, Kangsheng Gu, Guohua Yu, Zhonghan Zhang, Jiuwei Cui, Liyun Miao, Li Zhang, Xia Yuan, Yong Fang, Xiuhua Fu, Chengping Hu, Xiaoli Zhu, Yun Fan, Qitao Yu, Gang Wu, Ou Jiang, DU Xiu-ping, Jiwei Liu, Wei Gu, Zhiguo Hou, Quanren Wang, Rongrong Zheng, Xianfeng Zhou, Li Zhang, Li Zhang, Li Zhang
Topics & Concepts
ApatinibMedicineGefitinibInternal medicineOncologyClinical endpointProgression-free survivalHazard ratioT790MEpidermal growth factor receptorRandomized controlled trialConfidence intervalChemotherapyCancerLung Cancer Treatments and MutationsColorectal Cancer Treatments and StudiesRadiomics and Machine Learning in Medical Imaging